Rational use of drug and pharmaceutical care in patients with coronavirus disease 2019 combined with stroke

Coronavirus disease 2019 (COVID-19) patients are particularly critically ill, often accompanied by D-djurogen elevation, easy to induce or aggravate the occurrence of ischemic stroke. Both diseases have similar symptoms such as headache, vomiting, fever and shortness of breath in the early stages of their medical history, which can easily lead to misdiagnosis, missed diagnosis, and mutual influence, resulting in prolonged course of illness. For patients with COVID-19, anti-venom treatment should be actively taken as soon as possible, combined with stroke patients, the indicator change of D-diamer should be closely monitored, according to its indicators to give patients appropriate anti-thrombosis treatment, once the D-diamer rises, it is recommended to start anticoagulant immediately, while controlling the patient's blood pressure lipids and other high-risk factors. In this paper, combined with the research on stroke-related drug use, this paper discusses the rational drug use strategy and pharmacological care of high-risk groups such as COVID-19 combined with stroke, and provides reasonable drug use reference for such patients.